BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16447267)

  • 1. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus.
    Merola E; Mattioli E; Minimo C; Zuo W; Rabitti C; Cicala M; Caviglia R; Pollice L; Gabbrielli A; Giordano A; Claudio PP
    J Cell Physiol; 2006 May; 207(2):512-9. PubMed ID: 16447267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.
    Mattioli E; Vogiatzi P; Sun A; Abbadessa G; Angeloni G; D'Ugo D; Trani D; Gaughan JP; Vecchio FM; Cevenini G; Persiani R; Giordano A; Claudio PP
    J Cell Physiol; 2007 Jan; 210(1):183-91. PubMed ID: 16998811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cell cycle-regulated proteins pRB2/p130, p107, E2F4, p27, and pCNA in salivary gland tumors: prognostic and diagnostic implications.
    Russo G; Zamparelli A; Howard CM; Minimo C; Bellan C; Carillo G; Califano L; Leoncini L; Giordano A; Claudio PP
    Clin Cancer Res; 2005 May; 11(9):3265-73. PubMed ID: 15867222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pRb2/p130, vascular endothelial growth factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma: their clinical significance.
    Claudio PP; Russo G; Kumar CA; Minimo C; Farina A; Tutton S; Nuzzo G; Giuliante F; Angeloni G; Maria V; Vecchio FM; Campli CD; Giordano A
    Clin Cancer Res; 2004 May; 10(10):3509-17. PubMed ID: 15161709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
    Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
    Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus.
    Umansky M; Yasui W; Hallak A; Brill S; Shapira I; Halpern Z; Hibshoosh H; Rattan J; Meltzer S; Tahara E; Arber N
    Oncogene; 2001 Nov; 20(55):7987-91. PubMed ID: 11753681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.
    Tonini T; Bagella L; D'Andrilli G; Claudio PP; Giordano A
    Oncogene; 2004 Jun; 23(28):4930-7. PubMed ID: 15077161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.
    Howard CM; Claudio PP; De Luca A; Stiegler P; Jori FP; Safdar NM; Caputi M; Khalili K; Giordano A
    Cancer Res; 2000 May; 60(10):2737-44. PubMed ID: 10825149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
    Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination.
    Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M
    Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.
    Singh SP; Lipman J; Goldman H; Ellis FH; Aizenman L; Cangi MG; Signoretti S; Chiaur DS; Pagano M; Loda M
    Cancer Res; 1998 Apr; 58(8):1730-5. PubMed ID: 9563491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Rb, pRb2/p130, p53, and p16 proteins in malignant melanoma of oral mucosa.
    Tanaka N; Odajima T; Mimura M; Ogi K; Dehari H; Kimijima Y; Kohama G
    Oral Oncol; 2001 Apr; 37(3):308-14. PubMed ID: 11287287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
    Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
    Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
    J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
    J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunohistochemical study of p53, p27 and PCNA expression in esophageal cancer].
    Sakurai K; Hata S; Amano S; Kimura T; Hori A; Sakamoto A; Kimizuka K; Mimatsu K; Nishio S; Miyake H; Shibata M; Fukuzawa M
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1269-72. PubMed ID: 9703805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
    Wolters T; Vissers KJ; Bangma CH; Schröder FH; van Leenders GJ
    BJU Int; 2010 Jul; 106(2):280-6. PubMed ID: 19888978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
    Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
    J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.